SAB Biotherapeutics (SABS) Non-Current Assets (2020 - 2026)

SAB Biotherapeutics has reported Non-Current Assets for 7 years, with the latest figure at $135.7 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 521.76% year-over-year to $135.7 million; the trailing twelve-month figure through Mar 2026 stood at $298.4 million (up 247.84% YoY), and the FY2025 full-year result was $71.8 million, up 251.7% from the prior year.
• Non-Current Assets for Q1 2026 stood at $135.7 million, up from $71.8 million in the prior quarter.
• The five-year high for Non-Current Assets was $135.7 million in Q1 2026, with the low at $20.4 million in Q4 2024.
• Historically, Non-Current Assets has averaged $37.3 million across 5 years, with a median of $26.4 million in 2023.
• Annual changes were most pronounced in 2022 — Non-Current Assets plunged 73.89% — and 2026, when it jumped 521.76%.
• SAB Biotherapeutics' Non-Current Assets stood at $28.8 million in 2022, then decreased by 13.1% to $25.0 million in 2023, then retreated by 18.5% to $20.4 million in 2024, then soared by 251.7% to $71.8 million in 2025, then soared by 89.09% to $135.7 million in 2026.
• The last three Non-Current Assets figures came in at $135.7 million (Q1 2026), $71.8 million (Q4 2025), and $70.2 million (Q3 2025), per Business Quant data.